Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases
Authors' conclusion
Only 10.2% of eligible patients with SARDs received RSV vaccination. Glucocorticoid users were less likely to receive RSV vaccination, whereas specific SARD types and DMARDs were not associated.
Study context
- Population
- Patients with systemic autoimmune rheumatic diseases (SARDs) aged ≥ 60 years eligible for respiratory syncytial virus (RSV) vaccination between May 2023 and February 2025, Mass General Brigham (Boston, Massachusetts, USA)median age 71.7 years, 72.4% female
- Participants
- 10,587 patients
- Outcome
- RSV vaccine uptake and factors associated with RSV vaccination
Methodological detailsmultivariable logistic regression
- Multivariable logistic regression
Main finding
As reported in the abstract
RSV vaccination uptake
Eligible patients with SARDs
10.2%
1075 events
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Documented laboratory-confirmed RSV breakthrough infection among the vaccinated | Vaccinated 0.8% |
- Documented laboratory-confirmed RSV breakthrough infection among the vaccinated — Hospitalizations
- 2
- Documented laboratory-confirmed RSV breakthrough infection among the vaccinated — Deaths
- 0
- Documented laboratory-confirmed RSV breakthrough infection among the vaccinated: n = 1075 vaccinated
Original publication
Investigating Factors Associated With Respiratory Syncytial Virus Vaccination and Breakthrough Infection Among Patients With Systemic Autoimmune Rheumatic Diseases. J Rheumatol. Published 1 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →